Thus, the validation of standardized procedures for assessing PD-1/PD-L1 expression is paramount for establishing a reliable predictive marker of response, which is currently missing from our therapeutic armament for NHL patients. The gene discussed is PDCD1; the disease is non-Hodgkin lymphoma.